Between January 2010 and December 2022, there was a total of 699 patients diagnosed with advanced‐stage EGFR‐mutated NSCLC who received first‐line treatment with either the first‐ or second‐generation EGFR‐TKIs at NCKUH. This evidence concerns the gene EGFR and non-small cell lung carcinoma.